Agenus Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Agenus Inc 公司

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Agenus Inc简介



公司代码AGEN

公司名称Agenus Inc

上市日期Feb 04, 2000

CEOArmen (Garo H)

员工数量316

证券类型Ordinary Share

年结日Feb 04

公司地址3 Forbes Rd

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02421-7305

电话17816744400

网址https://agenusbio.com/

公司代码AGEN

上市日期Feb 04, 2000

CEOArmen (Garo H)

Agenus Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

29.77K

+7691.00%

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+15782.00%

Mr. Brian J. Corvese

Independent Director

4.60K

--

Wright (Timothy R)

Lead Independent Director

2.77K

--

Dr. Jennifer S. Buell, Ph.D.

Director

--

Ms. Susan F. Hirsch

Independent Director

--

Dr. Steven O'Day, M.D.

Chief Medical Officer

--

Mr. Richard Goldberg

Chief Development Officer

--

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

名称

名称/职务

职务

持股

持股变动

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

29.77K

+7691.00%

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+15782.00%

Mr. Brian J. Corvese

Independent Director

4.60K

--

Wright (Timothy R)

Lead Independent Director

2.77K

--

Dr. Jennifer S. Buell, Ph.D.

Director

--

Ms. Susan F. Hirsch

Independent Director

--

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Non-cash royalty revenue

29.15M

96.40%

Clinical product revenue

1.09M

3.60%

Other services

0.00

0.00%

地区USD

名称

营收

占比

United States

30.23M

100.00%

Rest of World

0.00

0.00%

业务

地区

业务USD

名称

营收

占比

Non-cash royalty revenue

29.15M

96.40%

Clinical product revenue

1.09M

3.60%

Other services

0.00

0.00%

股东统计

更新时间: 2月7日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

7.83%

Zydus Lifesciences Ltd

5.90%

Invus Public Equities Advisors, LLC

2.94%

Morgan Stanley & Co. LLC

1.37%

BlackRock Institutional Trust Company, N.A.

1.30%

其他

80.66%

持股股东

占比

The Vanguard Group, Inc.

7.83%

Zydus Lifesciences Ltd

5.90%

Invus Public Equities Advisors, LLC

2.94%

Morgan Stanley & Co. LLC

1.37%

BlackRock Institutional Trust Company, N.A.

1.30%

其他

80.66%

股东类型

持股股东

占比

Investment Advisor

16.06%

Corporation

5.90%

Investment Advisor/Hedge Fund

4.37%

Hedge Fund

3.03%

Research Firm

2.80%

Individual Investor

1.68%

Pension Fund

0.34%

其他

65.82%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

307

9.62M

26.67%

-3.78M

2025Q3

332

9.95M

41.39%

+217.92K

2025Q2

334

9.73M

47.54%

+407.61K

2025Q1

334

9.33M

45.75%

-2.82M

2024Q4

341

8.45M

52.98%

-249.79K

2024Q3

351

8.70M

54.68%

-447.45K

2024Q2

347

9.21M

64.12%

-1.91M

2024Q1

356

10.69M

65.28%

-2.98M

2023Q4

374

11.90M

61.88%

+645.94K

2023Q3

382

11.27M

62.51%

+267.62K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

2.57M

7.56%

+36.98K

+1.46%

Sep 30, 2025

Invus Public Equities Advisors, LLC

1.06M

3.13%

--

Sep 30, 2025

Morgan Stanley & Co. LLC

493.52K

1.45%

-226.23K

-31.43%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

468.79K

1.38%

-20.89K

-4.27%

Sep 30, 2025

Armen (Garo H.)

367.59K

1.08%

+9.26K

+2.58%

Dec 26, 2025

BofA Global Research (US)

369.31K

1.09%

-51.36K

-12.21%

Sep 30, 2025

Millennium Management LLC

348.75K

1.03%

-155.75K

-30.87%

Sep 30, 2025

Geode Capital Management, L.L.C.

346.99K

1.02%

+29.58K

+9.32%

Sep 30, 2025

Walleye Capital LLC

310.79K

0.91%

+112.50K

+56.74%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0%

iShares Russell 3000 ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

Fidelity Enhanced Small Cap ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

Schwab U.S. Small-Cap ETF

0%

SPDR Portfolio MSCI Global Stock Market ETF

0%

Global X Russell 2000 ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

iShares Micro-Cap ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0%

iShares Russell 3000 ETF

占比0%

Invesco NASDAQ Future Gen 200 ETF

占比0%

Fidelity Enhanced Small Cap ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

Schwab U.S. Small-Cap ETF

占比0%

SPDR Portfolio MSCI Global Stock Market ETF

占比0%

Global X Russell 2000 ETF

占比0%

Virtus LifeSci Biotech Clinical Trials ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

公告日期

除权除息日

类型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1